Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Philips Patient Monitors MX750 and MX850 have received 510(k) clearance from the FDA, enhancing their capabilities in acute care monitoring. These monitors are designed to optimize patient care with features like modularity, interoperability, and advanced infection control. The FDA clearance allows Philips to expand its monitoring capabilities in the U.S., building on their success in Europe since 2019. The monitors ensure real-time data flow to help clinicians manage patient care effectively.
Summary not available.
Philips (NYSE: PHG) has successfully treated its first patients using the innovative 3D Augmented Reality (AR) spine navigation solution, ClarifEye, at hospitals in Spain and Oman. This system, integrated with Azurion, allows for more accurate spine procedures through real-time imaging and navigation. The treatment of a 12-year-old patient with severe congenital spondylolisthesis and a 51-year-old with degenerative lumbar stenosis showcased significant improvements in surgical outcomes. The technology aims to enhance clinical accuracy, reduce postoperative complications, and facilitate the growing adoption of minimally invasive surgeries.
Philips (NYSE: PHG) unveiled its new CT 5100 – Incisive – featuring CT Smart Workflow at the RSNA annual meeting on November 29, 2021. This innovative technology uses artificial intelligence to streamline CT imaging processes, enhancing patient care while reducing operational costs. Key highlights include the Tube for Life guarantee, which could save up to USD 420,000 in lifetime operating costs. The CT Smart Workflow aims to improve efficiency and diagnostic confidence in radiology departments.
Royal Philips (NYSE: PHG) showcased its innovative portfolio of vendor-neutral radiology workflow solutions at the RSNA annual meeting from November 28 to December 2, 2021. The solutions focus on streamlining workflows for radiologists, technologists, and administrators through AI-driven informatics, enhancing diagnostic confidence and efficiency. Philips' new MR 5300 system, which received FDA 510(k) clearance, simplifies clinical tasks, while the company's commitment to sustainability is reinforced by its leadership in reducing CO2 emissions. Philips remains dedicated to improving healthcare outcomes and addressing workforce challenges in the radiology sector.
Philips has launched the world’s first spectral detector angio-CT solution at RSNA 2021, integrating breakthrough spectral CT imaging with real-time fluoroscopy. This innovative technology aims to enhance minimally invasive procedures in oncology, stroke, and trauma care. By combining the Spectral CT 7500 and Azurion with FlexArm, interventionalists gain immediate access to vital imaging modalities at the patient’s side, improving workflow and patient care. Philips is partnering with leading clinical institutions like Mayo Clinic to co-create this advanced imaging solution.
Royal Philips (NYSE: PHG) announced the launch of its new AI-powered MR 5300 and MR 7700 systems at the RSNA 2021 meeting. The MR 5300 system has received FDA 510(k) clearance and is designed for helium-free operations, enhancing sustainability and efficiency in outpatient clinics. The MR 7700 system features advanced multinuclear capabilities for improved imaging. Philips also introduced the AI-assisted MR Workspace, aimed at streamlining workflows and increasing productivity in radiology departments. The new portfolio emphasizes Philips' commitment to high-quality imaging and operational efficiency.
On November 22, 2021, Philips announced a collaboration with MedChat to integrate live chat and AI-driven chatbot services into its Patient Navigation Manager. This integration aims to enhance call center efficiency and expedite the resolution of patient inquiries in North America. The Patient Navigation Manager has shown significant success, with metrics indicating an 86% reduction in same-day cancellations and a 30% increase in referral conversions. The collaboration is part of Philips' commitment to improving patient management and outcomes through integrated health technology solutions.
Summary not available.
Philips (NYSE: PHG) has received FDA 510(k) clearance for its Liver Fat Quantification tools integrated into the EPIQ Elite and Affiniti ultrasound systems. This advancement aims to enhance early-stage fatty liver disease diagnosis, which affects about 25% of the global population. The tools will be showcased at the Radiological Society of North America annual meeting. Philips emphasizes that improved diagnostic capabilities will lead to better patient outcomes, allowing for timely lifestyle changes to mitigate liver disease progression.